GLP-1 receptors treatment: case reports
Authors:
Kamila Babjaková 1; Gabriela Hulinová 2; Zbynek Schroner 3
Authors‘ workplace:
Nemocnica AGEL Košice-Šaca a. s.
1; Nemocnica AGEL Zvolen a. s.
2; LF UPJŠ a SchronerMED, s. r. o. Košice
3
Published in:
Diab Obez 2021; 21(42): 95-97
Category:
Case studies
Sources
1. Davies MJ, D Alessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI:<http://dx.doi.org/10.1007/s00125–018–4729–5> .
2. Buse JB, Wexler DJ, Tsapas A et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2020; 43(2): 487- 493. Erratum for Buse JB, Wexler DJ, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43(7): 1670. Dostupné z DOI:<http://dx.doi.org/10.2337/dc20-er07>.
3. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné z DOI:<http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.
4. Buse JB, Wexler DJ, Tsapas A et al: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63(2) :221–228. Dostupné z DOI: . Erratum in Correction to: Buse JB, Wexler DJ, Tsapas A et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 2020; 63(8): 1667. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–020–05151–2>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2021 Issue 42
Most read in this issue
- New possibility in therapy of diabetes mellitus: co-formulation of insulin degludec and insulin aspart
- News in the field of SGLT2 inhibitors
- Compensation of social consequences of diabetes mellitus
- XXXIst diabetes days with international participation